[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 6, 1994

NIH Panel Report of 'No Flaws' in FIAU Trial at Variance With FDA Report, New Probe Planned

JAMA. 1994;272(1):9-11. doi:10.1001/jama.1994.03520010017006

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

THE TRAGIC deaths of five patients in a National Institutes of Health (NIH) study of the experimental hepatitis drug fialuridine or fluoroidoarauracil (FIAU) were, given the circumstances, "unavoidable" and due to a wholly new type of unexpected and delayed liver toxicity. There were no noteworthy flaws in the conduct of the study.

This is the conclusion of an exhaustive review of the situation conducted by a subcommittee of the NIH Director's Advisory Committee chaired by David R. Challoner, MD, vice president for health affairs, University of Florida College of Medicine, Gainesville, and David M. Kipnis, MD, distinguished university professor of medicine, Washington University School of Medicine, St Louis, Mo. The inquiry was conducted at the request of NIH Director Harold Varmus, MD, and the report presented at a committee meeting on June 2.

This report, the second to follow the deaths, could be viewed as at variance with an earlier

First Page Preview View Large
First page PDF preview
First page PDF preview
×